Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.
The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.
Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.
